Company Profile
Candel Therapeutics Stock Price, News & Catalysts
- Ticker:
- CADL
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
12.16 USD (+3.75%)
Close
Last updated: August 17, 2026
617M USD
Market cap
Why the stock is moving
As of Aug 17, 2026, CADL closed up 3.75% at $12.16. No new same-company headline was identified in the current news window.
Company overview
Multimodal Cancer Immunotherapy
Candel Therapeutics develops locally administered viral immunotherapies intended to induce immunogenic tumor-cell death and a systemic antitumor immune response.
Aglatimagene Besadenovec
Aglatimagene is an off-the-shelf, replication-defective adenovirus that delivers the HSV-thymidine-kinase gene into tumors. It is paired with valacyclovir to trigger local cytotoxicity and immune activation.
Prostate Cancer Program
A pivotal Phase 3 study demonstrated improved disease-free survival when aglatimagene was added to radiotherapy in localized intermediate- to high-risk prostate cancer. The company is preparing a BLA based on this program.
Lung Cancer Expansion
The global Phase 3 AURORA study evaluates aglatimagene in advanced non-squamous non-small-cell lung cancer progressing after pembrolizumab.
Linoserpaturev
Linoserpaturev is a replication-competent oncolytic herpes-simplex-virus therapy in development for recurrent glioblastoma and other solid tumors.
Future catalysts
- Submission of a BLA for aglatimagene in localized prostate cancer in the fourth quarter of 2026.
- Potential U.S. commercial launch of aglatimagene in 2027, subject to approval.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Candel Therapeutics (CADL)?
Candel Therapeutics (CADL) most recently closed at 12.16 USD, a +3.75% move versus the previous session.
What is the market cap of Candel Therapeutics (CADL)?
Candel Therapeutics currently has a market capitalization of 617M USD on BioPharmSignal.
What does Candel Therapeutics do?
Multimodal Cancer Immunotherapy Candel Therapeutics develops locally administered viral immunotherapies intended to induce immunogenic tumor-cell death and a systemic antitumor immune response. Aglatimagene Besadenovec Aglatimagene is an off-the-shelf, replication-defective adenovirus that delivers the HSV-thymidine-kinase gene into tumors. It is paired...
On which exchange is CADL stock listed?
Candel Therapeutics (CADL) is associated with NASDAQ, United States, Biopharma.
What is valacyclovir?
It is paired with valacyclovir to trigger local cytotoxicity and immune activation.
Which conditions is Candel Therapeutics targeting with valacyclovir?
Candel Therapeutics is associated with cancer therapeutics based on its company overview and current catalyst commentary.
How does Candel Therapeutics describe recent progress with valacyclovir?
Submission of a BLA for aglatimagene in localized prostate cancer in the fourth quarter of 2026. Potential U.S. commercial launch of aglatimagene in 2027, subject to approval.
What is pembrolizumab?
Lung Cancer Expansion The global Phase 3 AURORA study evaluates aglatimagene in advanced non-squamous non-small-cell lung cancer progressing after pembrolizumab.